Dupixent Stopped at UK Gate For AD As EMA Agrees To Review It In Asthma
Executive Summary
Dupixent has been initially rejected by NICE to treat eczema on cost grounds, but Sanofi remains hopeful of UK entry - and the biologic's overall promise.
You may also be interested in...
Pharma Q1 Results Preview: Shire, AbbVie, Bristol, Sanofi, Allergan
All eyes are on Shire in its first quarter of reporting separate figures for its neuroscience division as Takeda ramps up the takeover pressure, while BMS, AbbVie, Sanofi, and Allergan primes pipeline for revenue growth.
28 New Drug Approvals In EU: Cancer Dominates, But RA, Skin & Blood Disorders Well Served Too
Twenty-eight new products containing a total of 29 new active substances were authorized for marketing in the EU in 2017, very much line with the 2016 tally. As in that year, oncology dominated the 2017 approvals, which also included new drugs for rheumatoid arthritis, skin & blood disorders, and hepatitis C.
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.